Tempus (TEM) Q3 2026 Earnings Call Transcript
Tempus (TEM) reported Q3 2026 earnings, highlighting strategic collaborations with Bristol Myers Squibb, Moderna, and Merck, expected to generate $193M in revenue over 5 years. The company cleared regulatory review for its acquisition of Personalis, anticipating synergies in oncology diagnostics. Tempus reported $25.6M in adjusted EBITDA and $854M in cash, raising 2026 revenue guidance to $1.6B.
How this was made
The 30-second read
Why it matters
The new collaborations and guidance raise expectations for revenue growth, while the Personalis acquisition could expand market share in MRD testing.
Market read
Tempus' guidance lift and partnership announcements provide a fresh catalyst for the biotech sector, potentially moving the stock and related peers.
What to watch
Potential regulatory scrutiny of data licensing agreements and reimbursement headwinds for hereditary testing.
Background
Tempus delivered its Q3 2026 earnings call, reporting adjusted EBITDA of $25.6 m, $854 m cash, and outlining strategic collaborations and acquisition progress.
Ticker impact
Tempus announced new multi‑year collaborations with BMS, Moderna and Merck and raised FY2026 revenue guidance to $1.6 bn, providing fresh growth outlook.
likely upward pressure as investors price in higher revenue and partnership upside
The disclosed $193 m incremental revenue and $1.6 bn guidance are new, material numbers for a mid‑cap biotech, prompting a bullish reaction.
Market effects
Strengthens the oncology diagnostics and AI‑driven health‑data sector, may lift peers with similar partnership models.
Positive for US biotech and health‑tech equities.
Highlights growing pharma‑tech collaborations, could influence global biotech funding trends.
Counterpoint
Guidance may be optimistic; integration risk of Personalis and execution of multi‑year deals could delay revenue, limiting upside.
Key entities
- partnerBristol Myers Squibb
Licensing partner for oncology data and models.
- partnerModerna
Collaboration on individualized neoantigen therapy.
- partnerMerck
Joint development of neoantigen therapy and MRD assay distribution.
